High/JJ
frequency/NN
of/IN
germ-line/NN
BRCA2/NN
mutations/NNS
among/IN
Hungarian/JJ
male/JJ
breast/NN
cancer/NN
patients/NNS
without/IN
family/NN
history/NN
./.

To/TO
determine/VB
the/DT
contribution/NN
of/IN
BRCA1/NN
and/CC
BRCA2/NN
mutations/NNS
to/TO
the/DT
pathogenesis/NN
of/IN
male/JJ
breast/NN
cancer/NN
in/IN
Hungary/NNP
,/,
the/DT
country/NN
with/IN
the/DT
highest/JJS
male/JJ
breast/NN
cancer/NN
mortality/NN
rates/NNS
in/IN
continental/JJ
Europe/NN
,/,
a/DT
series/NN
of/IN
18/CD
male/JJ
breast/NN
cancer/NN
patients/NNS
and/CC
three/CD
patients/NNS
with/IN
gynecomastia/NN
was/VBD
analyzed/VBN
for/IN
germ-line/NN
mutations/NNS
in/IN
both/CC
BRCA1/NN
and/CC
BRCA2/NN
./.
=====
Although/IN
no/DT
germ-line/NN
BRCA1/NN
mutation/NN
was/VBD
observed/VBN
,/,
6/CD
of/IN
the/DT
18/CD
male/JJ
breast/NN
cancer/NN
cases/NNS
(/(
33/CD
%/NN
)/)
carried/VBD
truncating/JJ
mutations/NNS
in/IN
the/DT
BRCA2/NN
gene/NN
./.
=====
Unexpectedly/RB
,/,
none/NN
of/IN
them/PRP
reported/VBD
a/DT
family/NN
history/NN
for/IN
breast/ovarian/JJ
cancer/NN
./.
=====
Four/CD
of/IN
six/CD
truncating/JJ
mutations/NNS
were/VBD
novel/JJ
,/,
and/CC
two/CD
mutations/NNS
were/VBD
recurrent/JJ
./.
=====
Four/CD
patients/NNS
(/(
22/CD
%/NN
)/)
had/VBD
a/DT
family/NN
history/NN
of/IN
breast/ovarian/JJ
cancer/NN
in/IN
at/IN
least/JJS
one/CD
first-/JJ
or/CC
second-degree/JJ
relative/JJ
;/:
however/RB
,/,
no/DT
BRCA2/NN
mutation/NN
was/VBD
identified/VBN
among/IN
them/PRP
./.
=====
No/DT
mutation/NN
was/VBD
identified/VBN
in/IN
either/DT
of/IN
the/DT
genes/NNS
in/IN
the/DT
gynecomastias/NNS
./.
=====
These/DT
results/NNS
provide/VBP
evidence/NN
for/IN
a/DT
strong/JJ
genetic/JJ
component/NN
of/IN
male/JJ
breast/NN
cancer/NN
in/IN
Hungary/NNP
./.